Initiation of GLP-1 receptor agonists (GLP-1RAs) is associated with a 23% lower risk of hospitalization for heart failure (HHF) compared to DPP-4 inhibitors.
In a direct real-world comparison, GLP-1RAs demonstrated comparable effectiveness to SGLT-2 inhibitors in preventing HHF, with a weighted hazard ratio of 1.02.
The absolute risk reduction for HHF is most significant among patients with the highest baseline cardiovascular risk, suggesting a targeted approach for therapy escalation.
Target trial emulation methodology provides robust evidence that bridges the gap between restrictive randomized controlled trials and heterogeneous observational data.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
